EPIX Pharmaceuticals To Present At IBC's 12th Annual Drug Discovery & Development Of Innovative Therapeutics World Congress
Lexington, MA - EPIX Pharmaceuticals, Inc. recently announced that two members of the company's senior management team are scheduled to present and participate in the IBC Life Sciences 12th Annual Drug Discovery & Development of Innovative Therapeutics World Congress at the World Trade Center and The Seaport Hotel in Boston.
Chen Schor, CPA, chief business officer of EPIX, is scheduled to present "EPIX Pharmaceuticals: From GPCR Drug Discovery Technology to $1.2B Collaboration with GSK" on Monday, August 6, 2007 at 4:10 p.m. EDT. This presentation will focus on the strategic fit of EPIX's GPCR discovery technology and pipeline that led to the $1.2B collaboration between EPIX and GlaxoSmithKline. Later that same day, Mr. Schor is also scheduled to serve as the moderator for a panel discussion among five industry experts, "Trends in Discovery Stage Deals," at 5:00 p.m. EDT. This discussion will examine the competitive landscape in the bio-pharmaceutical arena, key considerations in early stage partnering from the licensee and the licensor perspectives and how these factors reflect on trends in collaboration structures and deal terms.
Additionally, J. Thomas Megerian, M.D., Ph.D., executive director, clinical research of EPIX, is scheduled to present "New Paradigms in Drug Discovery: A Case Study with PRX-03140" on Wednesday, August 8, 2007 at 2:35 p.m. EDT. This presentation will focus on PRX-03140, the company's novel, highly selective, small-molecule agonist of a specific GPCR known as 5-HT4 for the treatment of Alzheimer's disease. Currently in a phase 2a clinical trial as a single agent and in combination with Aricept in patients with mild Alzheimer's disease, PRX-03140 is one of the GPCR programs included in the worldwide multi-target strategic collaboration between EPIX and GlaxoSmithKline. Data from this trial are expected in late 2007.
SOURCE: EPIX Pharmaceuticals, Inc.